Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or preventing a disease, disorder and/or a condition related to inflammation, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: A method for modulating an immunoresponse includes binding a TREM-like transcript 1 (TLT-1) polypeptide to an immune cell, wherein the binding of the TLT-1 polypeptide to the immune cell suppresses immunoresponse. A method for treating and/or preventing a disease associated with immune hyper-reactivity includes administering the TLT-1 polypeptide to a subject in need thereof.

Abstract: Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating Globo-H-positive cancer.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: A method for treating alopecia and/or hair depigmentation includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-44 amino acid residues and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 16-35 of SEQ ID NO: 10. Also disclosed herein are pharmaceutical compositions containing the synthetic peptide; and uses thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in treating alopecia and/or hair depigmentation in a subject.

Abstract: A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.

Abstract: The invention relates to a use of an aurantiamide dipepetide derivative in the treatment or prevention of angiogenesis-related diseases. Accordingly, aurantiamide dipeptide derivatives can be used as angiogenesis inhibitor, whereby preventing or treating invasive and metastatic cancer and ocular neovascularization (particularly macular degeneration such as pathological neovascularization of age-related macular degeneration (AMD)).

Abstract: A sensor patch, system, and method for detecting a fluid leaked from a target site of a subject are provided. The sensor patch (100) includes a first detecting unit (127), a second detecting unit (128), and a patch body (110). The first detecting unit (127) includes a first pair of sensors (120A) respectively having a first end (121A) configured to be placed approximating the target site, while the second detecting unit (128) includes a second pair of sensors (120B) respectively having a first end (121B) configured to be placed away from the target site. Each sensor includes a conductive wire (125) and an insulating sheath (126) encapsulating the conductive wire (125) in a manner that a portion of the first end (121A, 121B) of the conductive wire (125) is exposed yet without directly contacting the subject's skin. The patch body (110) has an adhesive surface (104) for securing the first and second detecting units (127, 128) to the subject. The sensor patch enhances the detection specificity.

Abstract: Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating Globo-H-positive cancer.

Abstract: Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating Globo-H-positive cancer.

Abstract: A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Abstract: A device for measuring brain oxygen level of a subject, including a probe (210) and a detecting means (220), which are respectively coupled to a processor (230). According to the example, the probe (210) includes three light sources (215a, 215b, 215c) that simultaneously emit the first, second, and third NIR wavelengths across the brain of the subject. The first NIR wavelength is the isosbestic wavelength for oxy-hemoglobin (HbO2) and deoxy-hemoglobin (Hb), the second NIR wavelength is shorter than the first NIR wavelength, and the third NIR wavelength is longer than the first NIR wavelength. The detecting means (220) includes a first, second and third detectors (221, 222, 223) for respectively detecting the NIR intensities of the first, second and third NIR wavelengths traveled across the brain. The processor (230) is configured to determine blood oxygen level based on the measured NIR intensities of the first, second and third NIR wavelengths by use of build-in algorithm derived from Beer-Lambert Law.

Abstract: A fluid withdrawing, expelling and filtering apparatus includes a fluid container including a first chamber, a second chamber, and, a first through hole and a second through hole respectively disposed in communication between the first chamber and the second chamber, a filter device movable between a first position and a second position to open or close the second through hole of the fluid container and including a filter element mating with the first through hole, and a fluid withdrawing and expelling operator operable to withdraw and expel a fluid through the first chamber of the fluid container.

Abstract: A method for treating osteoarthritis in a subject includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Abstract: An evaluation system for determination of cardiovascular function parameters is provided. The evaluation system includes a data reading module, an image generating module, a contour determination module, an active contour module, a geometric center axis computing module, a view angle selection module and a function evaluation module. After reading cardiovascular graphic files with the data reading module, the image generating module displays 2D images or a 3D image constructed from the 2D images. Then, active contours are generated by the contour determination module and the active contour module, so as for the geometric center axis computing module to calculate geometric center axes. The view angle selection module then rotates the 3D image according to the view angle data received and modifies the 2D image files accordingly to generate plural cross-section images of the 3D image. Finally, the function evaluation module calculates evaluation parameters according to the geometric center axes.

Abstract: An ultrathin endoscope auxiliary system includes an overtube (110) and a mouth piece (150). The overtube (110), which allows the ultrathin endoscope (160) to be inserted therein, includes a transparent cap (112), a side opening (114), a deflecting member (180) and a positioning member (120). The transparent cap (112) is disposed at the front end of the overtube (110); the side opening (114) is disposed on the overtube (110) and approximates to the front end of the overtube (110); whereas the deflecting member (180) is disposed within the overtube (110) and the positioning member (120) is disposed outside the overtube (110) and approximates to the side opening (114). The deflecting member (180) is capable of deflecting the ultrathin endoscope and thereby allows the ultrathin endoscope (160) to be extended outside the overtube (110) through the side opening (114). The mouth piece (150) works with the overtube (110) to adjust the length and the axial orientation of the overtube (110) in the subject.

Abstract: Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer. Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer.

Abstract: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Abstract: The present invention provides a radiotherapy system that can monitor a target location in real time. The radiotherapy system includes a remote control system operable to actuate a real-time image capturing device to acquire images in real time for monitoring the target location. The system also includes an image registration system that can register the acquired image with an image previously captured for the treatment plan, whereby it can be determined whether the patient's tumor is in the beam's eye view of the treatment plan. By confirming that the tumor is in the range of the beam's eye view, the accuracy of the treatment can be improved, and the irradiated area can be reduced, which makes the radiation treatment safer.

Abstract: Disclosed herein are methods for treating an angiogenesis-related condition or disease in a subject in need thereof. Said method includes administering to the subject a peptide having at least 90% sequence identity of the sequence of SEQ ID NO: 1 or SEQ ID NO:3 in a therapeutically effective amount.